A Non-Hallucinogenic Psychedelic Analog with Therapeutic Potential
Cameron, Lindsay P., Tombari, Robert J., Lu, Ju, Pell, Alexander J., Hurley, Zefan Q., Ehinger, Yann, Vargas, Maxemiliano V., McCarroll, Matthew N., Taylor, Jack C., Myers-Turnbull, Douglas, Liu, Taohui, Yaghoobi, Bianca, Laskowski, Lauren J., Anderson, Emilie I., Zhang, Guoliang, Viswanathan, Jayashri, Brown, Brandon M., Tjia, Michelle, Dunlap, Lee E., Rabow, Zachary T., Fiehn, Oliver, Wulff, Heike, McCorvy, John D., Lein, Pamela J., Kokel, David, Ron, Dorit, Peters, Jamie, Zuo, Yi, Olson, David E. · 2021 · Nature
Mechanisms Preclinical moderate
AI-extracted · unverified · confirm at source
TBG: non-hallucinogenic ibogaine analog, ~100× lower hERG inhibition (IC₅₀ ~100 μM vs 1 μM), promotes neural plasticity via 5-HT2A, reduces alcohol/heroin-seeking in rodents with effects lasting 12–14 days
Safety data present: HERG